Nagy Habib, Chairman and Co-Founder, **MiNA Therapeutics**

Nagy Habib is Professor of Hepatobiliary Surgery and Academic Head of Surgery at Imperial College London, Hammersmith Hospital and Lead Clinician for liver cancer services at Imperial College NHS Healthcare Trust.

He is a translational researcher. Since 2002, Professor Habib has been working in the field of adult stem cells. He conducted the world's first phase I study of autologous adult bone-marrow derived stem cells in patients with liver disease. He has also completed studies in patients with ischaemic stroke and diabetes.

With other colleagues he developed a new technology with double stranded RNA that allows increased expression of a large number of genes in several types of cells. In particular, he pioneered the use of small activating RNA to CEPBa to improve liver function and induce tumour reduction in primary liver cancer.

He is also an inventor of surgical and medical devices. Nine years ago, with a team of engineers, he developed a surgical device (Habib™ 4X) that seals vascular tissue along a surgical plane, allowing the surgeon to remove tumours from the liver, pancreas, spleen, and kidneys with minimal blood loss. The device is now in routine use around the world.

Professor Habib has co-founded several biotech companies such as EMcision Limited, Delta 9/Medirace, Bioenvision, OmniCyte Limited, MiNA and Apatamer Limited. He has published over 290 papers and he serves on several committees for manuscript review.

He holds a Gold Award for clinical excellence and was one of the top ten surgeons cited in the Saturday Times newspaper.